MLICM
OVID icon

Metropolitan Life Insurance Company (MetLife)’s Ovid Therapeutics OVID Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-977
Closed -$2.98K – 1494
2024
Q1 		$2.98K Sell
977
-2,310
-70% -$7.73K ﹤0.01% 2278
2023
Q4 		$10.6K Hold
3,287
– – ﹤0.01% 2160
2023
Q3 		$12.6K Hold
3,287
– – ﹤0.01% 2111
2023
Q2 		$10.8K Buy
+3,287
New +$11.2K ﹤0.01% 2262
2020
Q4 		– Sell
-7,248
Closed -$41.6K – 2562
2020
Q3 		$41.6K Sell
7,248
-7,212
-50% -$48.3K ﹤0.01% 2483
2020
Q2 		$107K Buy
+14,460
New +$67.6K ﹤0.01% 2224

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OVID Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Ovid Therapeutics (OVID) in Q2 2024, closing a stake of 977 shares — an estimated $2.98K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OVID in Q2 2020 and held it in 6 quarters. The position peaked at $107K in Q2 2020. 74 funds tracked by Wall St. Rank hold OVID as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Ovid Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 977 Ovid Therapeutics shares in Q2 2024, an estimated $2.98K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Ovid Therapeutics in Q2 2020 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Ovid Therapeutics position peaked at $107K in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.